Boston Scientific Co. (NYSE:BSX) Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC increased its holdings in Boston Scientific Co. (NYSE:BSX) by 17.0% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 4,771,935 shares of the medical equipment provider’s stock after purchasing an additional 694,585 shares during the quarter. Fisher Asset Management LLC’s holdings in Boston Scientific were worth $399,888,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in BSX. Advisors Asset Management Inc. increased its holdings in shares of Boston Scientific by 45.6% during the first quarter. Advisors Asset Management Inc. now owns 7,544 shares of the medical equipment provider’s stock valued at $517,000 after purchasing an additional 2,361 shares during the period. Silvercrest Asset Management Group LLC raised its position in shares of Boston Scientific by 28.1% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 50,808 shares of the medical equipment provider’s stock worth $3,480,000 after buying an additional 11,138 shares in the last quarter. Kennedy Capital Management LLC acquired a new stake in shares of Boston Scientific in the 1st quarter worth approximately $3,021,000. B. Riley Wealth Advisors Inc. boosted its holdings in shares of Boston Scientific by 52.0% in the first quarter. B. Riley Wealth Advisors Inc. now owns 16,270 shares of the medical equipment provider’s stock valued at $1,114,000 after acquiring an additional 5,564 shares in the last quarter. Finally, Meiji Yasuda Life Insurance Co increased its stake in shares of Boston Scientific by 49.6% during the first quarter. Meiji Yasuda Life Insurance Co now owns 68,568 shares of the medical equipment provider’s stock valued at $4,696,000 after acquiring an additional 22,725 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the transaction, the director now directly owns 39,398 shares of the company’s stock, valued at $3,610,038.74. This represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 162,777 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the sale, the chief executive officer now directly owns 1,572,096 shares of the company’s stock, valued at $133,046,484.48. This represents a 9.38 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 314,147 shares of company stock worth $26,643,598. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Trading Down 1.6 %

NYSE BSX opened at $90.00 on Monday. The company has a market capitalization of $132.64 billion, a PE ratio of 74.38, a price-to-earnings-growth ratio of 2.69 and a beta of 0.79. Boston Scientific Co. has a 1-year low of $53.93 and a 1-year high of $91.93. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm’s fifty day simple moving average is $85.99 and its 200-day simple moving average is $80.22.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. The business had revenue of $4.21 billion during the quarter, compared to analysts’ expectations of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The firm’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.50 EPS. As a group, sell-side analysts anticipate that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on BSX. Stifel Nicolaus upped their target price on Boston Scientific from $85.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Bank of America raised their target price on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Truist Financial boosted their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Evercore ISI raised their price objective on shares of Boston Scientific from $82.00 to $90.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, Morgan Stanley boosted their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $93.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.